Wednesday, January 19, 2022
Home Tags PP Defence Therapeutics

PP Defence Therapeutics Related News

Defence Therapeutics achieves major milestone with anti-cancer molecule 

Defence Therapeutics achieves major milestone with anti-cancer molecule 

Biotechnology company Defence Therapeutics has announced the start of its final step in GLP studies on its anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited...
CRISPR

AccumTM platform greatly enhances CRISPR gene-editing technology

Defence Therapeutics has announced that its AccumTM platform can potently enhance Cas9 delivery in target cells, significantly advancing CRISPR gene-editing technology. The CRISPR technology offers...
Defence Therapeutics: changing the face of vaccines using AccumTM technology

Defence Therapeutics: changing the face of vaccines using AccumTM technology

Biotechnology specialists Defence Therapeutics are changing the face of vaccines using its AccumTM technology to enable precise delivery of proteins of pharmacological interest to...

Defence Therapeutics: Optimising drug efficacy with AccumTM technology

Health Europa is excited to introduce the latest captivating eBook from industry pioneers of the biotechnology sector, Defence Therapeutics, who comprehensively elucidate their revolutionary...
Defence Therapeutics

Defence Therapeutics announces exciting addition to its board of directors

Biotechnology specialists Defence Therapeutics has revealed today that Dr Riam Shammaa has been appointed to its board of directors. Dr Riam Shammaa, MD, is a...
new COVID vaccine

Defence Therapeutics successfully test new COVID vaccine

Defence Therapeutics has sensationally revealed that they have successfully completed studies of their new COVID vaccine in a non-rodent rabbit model. The innovative new COVID...
breast cancer

AccumTM variants successfully increase breast cancer treatment potency

Biotechnology experts Defence Therapeutics have revealed strong in vitro results of its AccumTM variants on the ADC breast cancer treatment called Enhertu® (fam-trastuzumab-deruxtecan-nxki), which...
cancer vaccine

Defence Therapeutics prepares to test its DC cancer vaccine against melanoma

Defence Therapeutics is finalising all required steps in preparation for a pre-IND meeting to initiate a phase I trial against melanoma using its DC cancer...
breast cancer treatment

Defence Therapeutics embark on next stage of breast cancer treatment development

In a groundbreaking development, pioneering biotechnology company Defence Therapeutics has announced today it will be performing the final necessary studies before entering a Phase...
new COVID vaccine

Defence Therapeutics’ new COVID vaccine achieves successful testing

Biotechnology experts Defence Therapeutics have sensationally announced that their new COVID vaccine has demonstrated effectiveness in a non-rodent model. The new COVID vaccine – called...
HPV vaccine

Defence Therapeutics unveil novel HPV vaccine development programme

Industry-leading biotechnology company Defence Therapeutics has revealed that it will be establishing a high priority programme to develop a new HPV vaccine for cervical...
Accum-vaccine

Versatile Accum technology for various immune-oncology needs

Defence Therapeutics explains how its Accum™ technology can enhance the delivery of tumour and infectious disease-specific therapeutics. The principal technology developed by Defence Therapeutics (DT)...
drug-delivery-Defence-Therapeutics

Defence Therapeutics selects new variants to optimise drug delivery

Following a thorough evaluation process, Defence Therapeutics has selected the eight most successful variants of its Accum™ drug delivery technology. Biotechnology company Defence Therapeutics continually works...
Defence Therapeutics

Defence Therapeutics: At the forefront of biotech innovation

In this article, we examine the future landscape of the Biotech sector, looking at the companies Defence Therapeutics, MorphoSys, BioNTech, and Pfizer. Infectious diseases are...
Defence-Therapeutics

Defence Therapeutics partners with pharmaceutical experts

Biotechnology company Defence Therapeutics has partnered with a pharmaceutical consultancy to maximise the potential of its developments. In a bid to strengthen its development of...
Collaboration formed to test efficacy of breast cancer therapy

Collaboration formed to test efficacy of breast cancer therapy

Defence Therapeutics Inc. has announced the establishment of a collaboration with the Curie Institute to evaluate the therapeutic efficacy of Accum-T-DM1 ADC in patient-derived...

Defence Therapeutics: Transforming drug delivery and improving treatment

Defence Therapeutics is continuously expanding on its portfolio of solutions to enhance drug delivery and improve treatment outcomes for patients with cancer and infectious...
Defence Therapeutics Accutox exhibits potent anti-cancer properties

Defence Therapeutics Accutox exhibits potent anti-cancer properties

Defence Therapeutics Inc. has announced a major breakthrough advance in its pre-clinical research program on its AccuTOX molecules as potent anti-cancer agents. The AccumTM technology...
Defence Therapeutics technology holds promise for future cancer therapy

Defence Therapeutics technology holds promise for future cancer therapy

Canadian biotechnology company Defence Therapeutics has developed a new generation platform technology that offers hope for future cancer therapy. Defence Therapeutics’ ACCUM™ technology can be...

Towards a cancer revolution with new targeted therapeutics

Defence Therapeutics Inc’s proprietary new platform offers a revolution in drug delivery. Quebec-based biotechnology developer Defence Therapeutics Inc specialises in antibody-drug conjugates (ADCs), a novel...

Health Special Reports

Health eBooks

Health Partners

Pin It on Pinterest